Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb Multicentre, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Study Evaluating Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

Trial Profile

A Phase IIb Multicentre, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Study Evaluating Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leflutrozole (Primary)
  • Indications Hypogonadism
  • Focus Therapeutic Use
  • Sponsors Mereo BioPharma

Most Recent Events

  • 01 Sep 2023 Results assessing the efficacy and safety/tolerability of the aromatase inhibitor leflutrozole to normalise testosterone in Obesity-associated Hypogonadotropic Hypogonadism published in the European Journal of Endocrinology
  • 18 Mar 2019 Results presented at the 101st Annual Meeting of the Endocrine Society
  • 15 Jan 2019 According to a Mereo BioPharma media release, abstract will be published online no later than 31 January 2019. It can be viewed after 31 January by searching for Mereo on the ENDO web program at https://www.abstractsonline.com/pp8/#!/5752.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top